Thursday, September 2, 2010

This is the end..... (to be continued)

The Pagoclone study is wrapping up - with results the drug company finds less than compelling, according to my contact at the research center that's been administering my participation in the study.

Many subjects, he tells me, have reported similar effects as those I have experienced: reduced tension in the larynx and/or articulators and at least some improvement in fluency. These positive effects are not powerful or compelling enough for the drug company to push for FDA approval at this time. My contact thinks they will engage in another study at a higher dose of the drug, with the hope that it will yield more promising results.

I am on my last three bottles of Pagoclone and will return to the research center in November for a final visit.

6 comments:

  1. Jim Dunlap here. I'm in the Pagoclone study too and I find it to be of great benefit. Letters to Endo Pharmaceutical may be critical to convincing them to continue the study. Here is the contact to the Endo CEO. Anyone hoping to benefit from Pagoclone should send the CEO a letter right now encouraging them to continue and explain how important this is to you. This may be our last chance. Please fax and mail an original.

    VIA FACSIMILE +1-610-558-7699 AND FIRST CLASS MAIL

    David P. Holveck, CEO
    Endo Pharmaceuticals
    100 Endo Boulevard
    Chadds Ford, PA 19317

    ReplyDelete
  2. Hi,

    I'm Martin from Germany, and I hope so much that Pagoclone reduces stuttering effectively. I'm 38 years old and I stutter since I'm 4 or 5 years old. Other kind of therapies are more or less an ineffective trial to cure the symptoms but not the mental cause. But the reports on this website awakens my hope.

    Could someone say when this medicament will be available on the market, especially in Europe? I'm afraid that it'll take some further years, or what do you think?

    Many greetings

    Martin

    ReplyDelete
  3. what's the matter?

    ReplyDelete
  4. Thanks for the comments, everyone.

    I've written the Endo CEO, as Jim suggested. Thanks for that info, Jim. Providing some direct feedback to the pharma company is a good idea.

    ___


    Martin, I doubt Pagoclone will hit the market in the US in the near term - we are probably looking at a few years at least. But there are other anti-anxiety drugs that may offer a measure of relief. You may want to speak to your doctor about it and see what's available. I may do this after my participation in the trial ends in November. Anything that lowers my level of stress makes it easier to apply techniques to improve fluency. Thanks for commenting and good luck.

    ___


    Anonymous, Matter has many definitions, but the most common is that it is any substance which has mass and occupies space. All physical objects are composed of matter, in the form of atoms, which are in turn composed of protons, neutrons, and electrons.

    Photons have no mass, so they are an example of something in physics is not comprised of matter. They are also not considered "objects" in the traditional sense, as they cannot exist in a stationary state.

    Matter can exist in various phases: solid, liquid, gas, or plasma. Most substances can transition between these phases based on the amount of heat the material absorbs (or loses).

    Hope this helps.

    ReplyDelete
  5. to be continued ?

    best regards

    Holger

    ReplyDelete
  6. Still hoping here, but i've searched for recent updates regarding Pagoclone and have found nothing.

    ReplyDelete